About: Vatalanib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth. Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.

Property	Value
dbo:abstract	Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth. Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2. (en)
dbo:casNumber	212141-54-3
dbo:chEBI	90620
dbo:chEMBL	101253
dbo:drugbank	DB04879
dbo:fdaUniiCode	5DX9U76296
dbo:pubchem	151194
dbo:thumbnail	wiki-commons:Special:FilePath/Vatalanib.svg?width=300
dbo:wikiPageExternalLink	http://clinicaltrials.gov/ct2/results%3Fintr=%22Vatalanib%22
dbo:wikiPageID	20341296 (xsd:integer)
dbo:wikiPageLength	7000 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1033009591 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Cancer dbr:VEGF_receptors dbr:C-kit dbr:Hypertension dbr:Patrick_Swayze dbr:Road_House_(1989_film) dbr:Colorectal_cancer dbr:Chemotherapy_regimen dbr:Nausea dbr:Small_molecule dbr:Pyrimidine_analogue dbr:Enzyme dbc:Experimental_cancer_drugs dbr:Liver dbr:Statistical_significance dbr:Clinical_endpoint dbr:Clinical_trial dbr:Protein_kinase_inhibitor dbr:Drug_discovery dbr:Fatigue_(medical) dbr:First-line_treatment dbr:Angiogenesis dbr:Angiogenesis_inhibitor dbr:Novartis dbr:Pancreatic_Cancer dbr:Diarrhea dbr:Kinase_insert_domain_receptor dbr:Vomiting dbr:Randomized_controlled_trial dbc:Angiogenesis_inhibitors dbr:International_Nonproprietary_Name dbr:Irinotecan dbc:Tyrosine_kinase_inhibitors dbr:Adverse_drug_reaction dbr:Chemotherapy dbr:Kidney dbr:Lactate_dehydrogenase dbr:High-throughput_screening dbr:Dirty_Dancing dbr:Dizziness dbr:CYP3A4 dbr:Metastasis dbr:National_Institutes_of_Health dbr:FOLFOX dbr:Platelet-derived_growth_factor_receptor dbr:Bayer_Schering_Pharma dbr:Progression_Free_Survival
dbp:atcPrefix	none (en)
dbp:bioavailability	High (en)
dbp:c	20 (xsd:integer)
dbp:casNumber	212141 (xsd:integer)
dbp:chebi	90620 (xsd:integer)
dbp:chembl	101253 (xsd:integer)
dbp:chemspiderid	133257 (xsd:integer)
dbp:cl	1 (xsd:integer)
dbp:drugbank	DB04879 (en)
dbp:eliminationHalfLife	3960.0
dbp:excretion	Fecal and renal (en)
dbp:h	15 (xsd:integer)
dbp:iupacName	N--4-phthalazin- 1-amine (en)
dbp:iupharLigand	5705 (xsd:integer)
dbp:legalStatus	Investigational (en)
dbp:metabolism	Extensive hepatic metabolism (en)
dbp:n	4 (xsd:integer)
dbp:pregnancyCategory	None assigned (en)
dbp:pubchem	151194 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	Clc1cccNc3nncCc4ccncc4 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	YCOYDOIWSSHVCK-UHFFFAOYSA-N (en)
dbp:unii	5 (xsd:integer)
dbp:width	180 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Chemotherapeutic_agents dbt:Clear dbt:Distinguish dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Stdinchicite
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Angiogenesis_inhibitors dbc:Tyrosine_kinase_inhibitors
gold:hypernym	dbr:Inhibitor
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAngiogenesisInhibitors yago:WikicatTyrosineKinaseInhibitors yago:Agent114778436 yago:AngiogenesisInhibitor102711422 yago:Antineoplastic102722458 yago:CausalAgent100007347 yago:CytotoxicDrug103157987 yago:Drug103247620 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:TyrosineKinaseInhibitor104506005 yago:WikicatExperimentalCancerDrugs
rdfs:comment	Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth. Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2. (en)
rdfs:label	Vatalanib (en)
owl:differentFrom	dbr:Vandetanib
owl:sameAs	freebase:Vatalanib yago-res:Vatalanib wikidata:Vatalanib dbpedia-sh:Vatalanib dbpedia-sr:Vatalanib https://global.dbpedia.org/id/4xoFv
prov:wasDerivedFrom	wikipedia-en:Vatalanib?oldid=1033009591&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Vatalanib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Vatalanib
is dbo:wikiPageRedirects of	dbr:PTK/ZK dbr:PTK787 dbr:PTK787/ZK_222584
is dbo:wikiPageWikiLink of	dbr:Patrick_Swayze dbr:MY-5445 dbr:VEGFR-2_inhibitor dbr:List_of_drugs:_V–Ve dbr:PTK/ZK dbr:PTK787 dbr:PTK787/ZK_222584
is foaf:primaryTopic of	wikipedia-en:Vatalanib

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License